Navigation Links
Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
Date:2/27/2013

RICHMOND, Calif., Feb. 27, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Geoff Nichol , M.B., Ch.B., Sangamo's executive vice president, research and development, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10:40 am ET on Wednesday, March 6, 2013, at the 33rd Annual Cowen and Company Health Care Conference which will be held in Boston.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
6. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
7. Neurocrine Biosciences Reports First Quarter 2012 Results
8. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
9. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
10. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
11. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ATLANTA , Feb. 10, 2016  LexisNexis® ... and technology, today announced the launch of ... analytics solution that helps improve and optimize the ... evaluation of performance using severity-adjusted scores. By measuring ... a critical solution to deliver better outcomes, improve ...
(Date:2/10/2016)... VIEW, Calif. , Feb. 10, 2016 ... of a synergistic confluence of various technologies ... value propositions, previously unavailable. These opportunities create ... and convergence, in turn, drives the development ... entrepreneurial scenario is characterized by technology convergences, ...
(Date:2/10/2016)... Mast Therapeutics, Inc. (NYSE MKT: ... sickle cell disease and heart failure, today announced the ... at a price to the public of $0.275 per ... Company,s common stock and one warrant to purchase one ... price of $0.42 per share. The warrants are exercisable ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined the ... available to physicians. The integration will enable Allscripts users to post open appointments ... free mobile app. , The partnership gives Everseat substantial added power to help ...
(Date:2/10/2016)... Jacksonville, Florida (PRWEB) , ... ... ... of North Florida – 1 UNF Drive, Jacksonville, FL 32224, February 26th: ... $30, February 27th: Elite Division - Time: 7:00pm – 10:00pm | Ticket ...
(Date:2/10/2016)... ... 2016 , ... Workrite Ergonomics, who is celebrating their 25th year of business ... being an internationally recognized leader in their industry. , "We are very proud of ... of Workrite. “Workrite recognized the importance of good ergonomics before most of our ...
(Date:2/10/2016)... ... , ... Anxiety of older Americans over steep cost increases of prescription drugs ... ago, according to The Senior Citizens League (TSCL). Since last fall, ... rapidly rising costs. “The implications are chilling, particularly for people with chronic health ...
(Date:2/10/2016)... Puente, California (PRWEB) , ... February 09, 2016 ... ... Medicine students, faculty and staff helped give free oral screenings to 150 children ... Feb. 5, 2016. , The College of Dental Medicine joined Chinese American Dental ...
Breaking Medicine News(10 mins):